Navigation Links
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
Date:11/12/2008

lso reported visiting an average of 4.4 different physicians before receiving an accurate diagnosis of HAE. In addition, survey participants had an average of two immediate and two extended family members that had been diagnosed with HAE, but only 48 percent of their immediate family members and 26 percent of their extended family members had been tested for HAE.

"Accurate, timely diagnosis of HAE patients continues to be a challenge, and despite the fact that HAE is a hereditary disorder, testing family members is not common practice; a consensus statement may lead to improved and earlier diagnosis of patients with HAE," said Timothy Craig, DO, professor of medicine, Penn State University, who co-presented the survey data. "These findings indicate that testing family members for HAE should be a primary concern for those caring for patients with the disorder, and patients should be alerted to the need for screening of their family members."

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the fiscal year ended December ... in Canadian dollars unless otherwise stated. ... the right strategic partners and additional capitalization in ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... , April 30, 2015  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... America Merrill Lynch 2015 Healthcare Conference on Thursday, May ... and Chief Executive Officer, will provide an update on ... (1:40 p.m., Eastern Daylight Time). The presentation ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
... WELLINGTON , Fla., May 10 Dr. ... children with newly diagnosed type 1 diabetes for Protege Encore, ... second of two Phase III studies testing the safety and ... known as Protege, has completed enrollment of more than 530 ...
... Ireland , May 10 Warner Chilcott plc ... of America Merrill Lynch Healthcare Conference on Tuesday, May 11, 2010 ... be Paul Herendeen , Executive Vice President and Chief Financial Officer. , ... Warner Chilcott ,s presentation will be ...
Cached Medicine Technology:Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2
... & Full Year 2008 Earnings Conference Call , Thursday, February 12, ... Jan. 12 Cephalon, Inc . (Nasdaq: CEPH ... quarter and full year 2008 results for 5:00 p.m. EST on ... 4:10 p.m. EST Q4 & FY 2008 ...
... a sagging economy? Not necessarily the quick fix that you ... plastic surgeons.Recently, the U.S. Food and Drug Administration (FDA) gathered ... the use of dermal fillers. Although the injections have been ... (the creases running from the nose to the corners of ...
... Beginning Thursday, January 15, 2009, cosmetic surgeons from around ... Cosmetic Surgery,s 25th Anniversary Scientific Meeting to share and ... A Day Over Twenty-five" will be held from January ... Ridge Resort and Spa in Phoenix, Arizona.AACS continues its ...
... to study inherited susceptibility for skin cancer in mice. In the process, ... role in controlling this susceptibility. The technique, the scientists say, could ... ... January 12, 2009 -- UCSF researchers have used a new ...
... Steve Shulman to BoardHOUSTON, Jan. 12 Access ... of outsourced medical implantable device management solutions to ... board of directors has appointed board member Steve ... appointment following its second consecutive year of revenue ...
... of minimally invasive surgery procedures in operating theatres. However, ... much to be desired. Researcher Magdalena Chmarra has changed ... system which records and analyses the surgeon,s movements. As ... an objective benchmark for measuring a surgeon,s basic skills ...
Cached Medicine News:Health News:Dr. Sherrell Aston Addresses the Popularity of Dermal Fillers and Possible Long Term Side Effects 2Health News:The State of the Cosmetic Surgery Industry is Discussed at AACS 25th Anniversary Scientific Meeting 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 3Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 4Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 2Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 3Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: